[A18-70] Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37
Last updated 06.12.2018
Commission awarded on 22.10.2018 by the Federal Joint Committee (G-BA).
Treatment-naive adults with advanced renal cell carcinoma (intermediate or poor risk)
Conclusion of dossier assessment A18-37 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-37||Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|